Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01088932 · ClinicalTrials.gov registry record · Phase 1

Multiple Dose Safety Study of SRX246 Capsules in Healthy Volunteers

A Phase 1 study of Healthy, sponsored by Azevan Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
24
Enrollment target
1
Study location

NCT01088932: Completed Phase 1 study of Healthy, sponsored by Azevan Pharmaceuticals.

NCT01088932 is a Phase 1 study of Healthy that has completed, run by Azevan Pharmaceuticals. The registered enrollment target is 24 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01088932, a Phase 1 study of Healthy, has completed, sponsored by Azevan Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

This is a multiple dose clinical study to be conducted with SRX246 capsules to determine the safety, tolerability and pharmacokinetics of the drug over a 14 day dosing period.

Conditions Studied

Interventions

  • DRUG SRX246

Study Locations (1)

Maryland

  • SNBL Clinical Pharmacology Center - Baltimore

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2010-03
Est. Completion 2010-07
Phase Phase 1

Sponsor

Azevan Pharmaceuticals

8 total trials

What the Registry Record Tells You About NCT01088932

The ClinicalTrials.gov registry entry for NCT01088932 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The listed sponsor is Azevan Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which SRX246 is the first listed.

NCT01088932 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT01088932 about?

NCT01088932 is a clinical study titled "Multiple Dose Safety Study of SRX246 Capsules in Healthy Volunteers". This is a multiple dose clinical study to be conducted with SRX246 capsules to determine the safety, tolerability and pharmacokinetics of the drug over a 14 day dosing period.

What is the current status of trial NCT01088932?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2010-03. Estimated completion is 2010-07.

What conditions does trial NCT01088932 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT01088932?

The interventions under investigation include: SRX246 (DRUG).

Who is sponsoring clinical trial NCT01088932?

This trial is sponsored by Azevan Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01088932 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.